- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 00:01 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 21.10.2024 | 87 | Xetra Newsboard | The following instruments on XETRA do have their first trading 21.10.2024 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 21.10.2024
Aktien
1 AU000000ARB5 ARB Corporation Ltd.
2... ► Artikel lesen | |
| 14.10. | ViroGates A/S: ViroGates announces a distribution agreement with suPAR Health and a directed issue of shares to suPAR Remedy LLC | 15 | GlobeNewswire (Europe) | Company Announcement no. 8/2024 (October 14, 2024)
ViroGates announces an agreement with US-based suPAR Health to distribute its blood test for chronic inflammation within the United States. ViroGates... ► Artikel lesen | |
| 15.08. | ViroGates A/S: ViroGates announces its half-year report for H1 2024: Revenue for the first half-year of 2024 falls behind the same period in 2023 due to lower activity among research customers | 4 | GlobeNewswire (Europe) | Company Announcement no. 7/2024 (August 15, 2024)
Inside informationBIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better... ► Artikel lesen | |
| 17.07. | ViroGates A/S: ViroGates announces revised financial guidance for 2024 | 4 | GlobeNewswire (Europe) | Company Announcement no. 6/2024 (July 17, 2024)
Inside informationBIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for better triaging... ► Artikel lesen | |
| 02.05. | ViroGates A/S: ViroGates announces its Interim Report for Q1, 2024: Quarterly revenue up 14% compared to Q1, 2023 | 4 | GlobeNewswire (Europe) | 2.5.2024 11:20:15 CEST | ViroGates |
Interim information
COMPANY ANNOUNCEMENT - No. 5-2024 - 02 May 2024- Inside information
BIRKERØD, DENMARK - ViroGates A/S announces its Interim Report for the... ► Artikel lesen | |
| 20.12.23 | First North Denmark: ViroGates A/S - increase | 268 | GlobeNewswire | New shares in ViroGates A/S will be admitted to trading on Nasdaq First North
Growth Market Denmark as per 21 December 2023. New shares are issued due to
completion of a rights issue.
Name:... ► Artikel lesen | |
| 24.11.23 | First North Denmark: ViroGates A/S - rights issue - admission to trading of subscription rights | 254 | GlobeNewswire | Subscription rights in ViroGates A/S will be admitted to trading on Nasdaq
First North Growth Market Denmark as per 28 November 2023. As of the same date,
ISIN DK0061030574 (VIRO) will be traded exclusive... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BEAM THERAPEUTICS | 23,650 | 0,00 % | Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results | U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) More than 20 Patients Enrolled and Six Patients Dosed... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,21 | 0,00 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
| DYNE THERAPEUTICS | 35,240 | 0,00 % | Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 23,671 Shares of Stock | ||
| HARMONY BIOSCIENCES | 35,410 | 0,00 % | Mizuho bullish on Harmony Biosciences stock, sees 2025 breakout potential | ||
| SPRINGWORKS THERAPEUTICS | 30,970 | 0,00 % | SpringWorks Therapeutics, Inc.: FDA Grants Priority Review to SpringWorks Therapeutics' New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN | - PDUFA target action date of February 28, 2025 - - EU Marketing Authorization Application also validated by European Medicines Agency - STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 73,20 | 0,00 % | Praxis Precision Medicines überarbeitet Abfindungsregelungen für Führungskräfte | ||
| TARSUS PHARMACEUTICALS | 36,620 | 0,00 % | Tarsus taps actor Betsy Sodaro to embody a 'mitey problem' in 1st Xdemvy DTC TV ad | ||
| SUMMIT THERAPEUTICS | 21,215 | 0,00 % | Summit Therapeutics (NASDAQ:SMMT) Trading Down 5% - Should You Sell? | ||
| VERA THERAPEUTICS | 41,160 | 0,00 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 16,080 | 0,00 % | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter... ► Artikel lesen | |
| 180 LIFE SCIENCES | 5,100 | 0,00 % | 180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform | PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Officer... ► Artikel lesen | |
| EVOTEC | 5,825 | +0,34 % | Evotec Aktie: Ist die große Chance gekommen? | In den letzten Tagen zeigte die Evotec Aktie deutliche Lebenszeichen. Nach der Bestätigung der starken charttechnischen Unterstützung oberhalb von 5,06 Euro kam es zu einem Kursanstieg binnen drei Tagen... ► Artikel lesen | |
| QIAGEN | 39,335 | -0,11 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen auf "Kaufen" mit einem fairen Wert von 50 Euro belassen. Der Labordienstleister und Diagnostikspezialist verfüge u?ber ein ausgezeichnetes... ► Artikel lesen | |
| BIOVIE | 2,320 | 0,00 % | BioVie sichert sich Patent für Terlipressin-Formulierung | ||
| ARCTURUS THERAPEUTICS | 21,150 | 0,00 % | Pad Chivukula Sells 12,000 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock |
VIROGATES A/S gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIROGATES A/S finden Sie auf Wallstreet Online.
